Recursion Pharmaceuticals, Inc. $RXRX Holdings Lowered by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 69.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 246,757 shares of the company’s stock after selling 571,559 shares during the quarter. Hsbc Holdings PLC’s holdings in Recursion Pharmaceuticals were worth $753,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cherry Creek Investment Advisors Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 5.8% in the first quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock worth $217,000 after buying an additional 3,859 shares during the period. Axxcess Wealth Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 16.6% during the first quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock valued at $115,000 after acquiring an additional 5,338 shares during the period. R Squared Ltd lifted its position in shares of Recursion Pharmaceuticals by 52.3% in the 1st quarter. R Squared Ltd now owns 32,363 shares of the company’s stock valued at $99,000 after acquiring an additional 11,118 shares in the last quarter. Integral Investment Advisors Inc. acquired a new position in Recursion Pharmaceuticals in the 1st quarter worth approximately $39,000. Finally, QRG Capital Management Inc. purchased a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $47,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $2.97 on Thursday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -2.47 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $3.32 and a 200 day simple moving average of $3.52.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same quarter in the previous year, the company posted ($0.50) earnings per share. The business’s quarterly revenue was down 56.8% compared to the same quarter last year. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on RXRX. JPMorgan Chase & Co. reduced their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Morgan Stanley upped their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.10.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director directly owned 6,218,287 shares in the company, valued at $24,624,416.52. The trade was a 0.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,937 shares of company stock valued at $486,974 over the last ninety days. Company insiders own 6.65% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.